The application describes a method for producing a population of cardiac stromal cells from pluripotent stem cells. Specifically, the method relates to (i) inducing epithelial-mesenchymal transition of pluripotent stem cell derived epicardial cells and (ii) amplifying the number of cardiac stromal cells in serum-free conditions. These cardiac stromal cells can be mass produced according to the described method and said cells maintain the expression of CD90, CD73 and CD44 in at least 80% of the cardiac stromal cells. Furthermore, the application relates to a population of cardiac stromal cells, which are pluripotent stem cells derived and wherein at least 80% of the cardiac stromal cells express CD90, CD73 and CD44. Said cardiac stromal form the basis for several in vitro and in vivo applications such as the production of engineered organ tissue and the support of, for example, heart repair. Also, a serum- free culture medium for the amplification of cardiac stromal cells is provided herein.

Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells.

The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.

The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.

The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.

Embodiments of the present disclosure relate generally to the production of therapeutic mesenchymal stem cells (MSCs). More particularly, the present disclosure relates to the use of cell culture compositions and methods for generating MSCs that secrete neurotrophic factors and synaptic organizing agents for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). As such, the present disclosure addresses the need for establishing a reliable source of therapeutic stem cells useful for the treatment of neurodegenerative diseases.

The present invention relates to an ex vivo method for producing platelets including a combination of use of pharmacological substances and microfluidic device features, for high yield and high quality platelet production from megakaryocytes or their progenitors.

The present invention relates to monolayer cardiac differentiation techniques utilizing defined conditions providing feeder-free monolayer culture systems, serum-based or serum free, and applicable to both healthy control and patient derived stem cells.

The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.

The present application provides methods and processes for making and using a fibronectin composition, as well as methods for treating ocular conditions and/or disorders with the cellular fibronectin composition described herein.